Neuroblastoma

Double Autologous HCT Improves Outcomes in High-risk Pediatric Neuroblastoma

By

Adding a second autologous hematopoietic cell transplantation (HCT) to standard therapy improves outcomes for pediatric patients with high-risk neuroblastoma.

New Therapy Holds Potential for Neuroblastoma Treatment

New Therapy Holds Potential for Neuroblastoma Treatment

By

A new therapy might help treat a rare, high-risk cancer that begins development in the fetus or embryo, neuroblastoma, according to recent results from cell culture experiments.

Novel Drug Effective in Treatment Resistant Pediatric Neuroblastoma

Novel Drug Effective in Treatment Resistant Pediatric Neuroblastoma

By

Researchers in pediatric oncology identified a powerful new drug with unparalleled strength against neuroblastomas that resist treatment with crizotinib.

Targeted Chemotherapy Shows Early Signs of Slowing Tumor Growth With Less Toxicity

By

Surviving neuroblastoma as a child can come with just as many challenges as the cancer itself. But a team of surgeons is in the nascent stages of developing a more targeted method for delivering chemotherapy, with lower toxicity.

Promising phase 1 results for difluoromethylornithine in neuroblastoma

By

In the first clinical trial of difluoromethylornithine (DFMO), an investigational agent for children suffering from neuroblastoma, side effects were minimal and patients saw long-term survival.

Identifying mutations in relapsed pediatric neuroblastoma may lead to better treatment options

Identifying mutations in relapsed pediatric neuroblastoma may lead to better treatment options

Majority of pediatric patients with relapsed neuroblastoma studied harbored mutations that promoted RAS-MAPK pathway signaling.

FDA greenlights dinutuximab to treat high-risk neuroblastoma

FDA greenlights dinutuximab to treat high-risk neuroblastoma

First approval for a therapy aimed specifically to treat the rare pediatric cancer

Alternative DNA repair mechanism could provide better treatment for neuroblastoma in children

By

A promising target for developing new therapies for children with high-risk neuroblastoma has been found.

Classifying gene mutations in neuroblastoma may point to improved treatments

By

Oncology researchers studying gene mutations in the childhood cancer neuroblastoma are refining their diagnostic tools to predict which patients are more likely to respond to the drugs that target these mutations.

US and Australian Researchers Form Alliance to Facilitate Development of Treatments for Childhood Cancers

US and Australian Researchers Form Alliance to Facilitate Development of Treatments for Childhood Cancers

Alliance of Australian and U.S. researchers and children's cancer advocates focused on developing drugs as potential treatments for neuroblastoma, the most common solid form of childhood cancer.

'Excellent' survival in biology-based pediatric neuroblastoma treatment reduction

By

Tumor biology-based therapy offers excellent outcomes among children with intermediate risk neuroblastoma, according to results from a prospective phase 3 reduction of therapy study.

Experimental treatment shows early promise for advanced neuroblastoma in children

By

Tumors shrank or disappeared and disease progression was temporarily halted in 15 children with advanced neuroblastoma enrolled in a safety study of an experimental antibody.

Differentiation therapy holds promise as a targeted therapy for pediatric neuroblastoma

By

The important role of microRNAs in regulating neuroblastoma development has been unveiled by new research.

Proton radiation a good option in high-risk neuroblastoma

By

Proton therapy offered the optimal combination of target coverage and organ-sparing in a recent study involving children with high-risk neuroblastoma.

Screening reveals potential alternative drug therapies for neuroblastoma

By

A new genomic approach for screening compounds has identified a compound that causes neuroblastoma cells to differentiate. This new strategy screens for compounds that could inhibit tumor growth by causing cancer cells to differentiate.

Conditioning decision for neuroblastoma transplants informed by toxicity differences

By

The stem cell transplant regimen that was commonly used in the United States to treat advanced neuroblastoma in children appears to be more toxic than the equally effective regimen employed in Europe and Egypt, according to a new study.

Biomarker may help identify neuroblastomas vulnerable to a novel class of drugs

By

An irregularity within many neuroblastoma cells may indicate whether a neuroblastoma tumor is vulnerable to a new class of anti-cancer drugs known as BET bromodomain inhibitors.

Biomarker may identify neuroblastomas with sensitivity to BET bromodomain inhibitors

By

Neuroblastoma is frequently associated with the presence of MYCN amplification, a genetic biomarker associated with poor prognosis. Researchers have determined that these tumors are sensitive to a new class of drugs.

Dendritic cell vaccine induced complete remission of relapsed neuroblastoma

By

Complete remission was achieved in a 6-year-old boy with recurrent neuroblastoma. One year after his last dendritic cell treatment, the boy shows no evidence of disease.

Surgery doesn't up pediatric neuroblastoma outcomes

Surgery doesn't up pediatric neuroblastoma outcomes

Extent of first or best surgery has no impact on overall, event-free, progression-free survival.

Annual report highlights 2012 cancer advances

The American Society of Clinical Oncology has released a nearly 100-page report detailing the year's most significant developments in cancer.

"Bully" genes found in common childhood tumor

By

Pediatric patients with neuroblastoma who have mutations in two genes, ARID1A and ARID1B, survive only a quarter as long as patients without the changes. This discovery could eventually lead to early identification of patients with aggressive neuroblastomas.

Whole-genome scan helps select best treatment for children with neuroblastoma

By

Identifying large-scale chromosomal damage through a whole-genome scan can help doctors choose the best option for treatment of neuroblastoma in children.

Colorectal risk defined for childhood cancer survivors

Childhood cancer survivors may need earlier colorectal cancer screening, especially if abdominal radiation was part of their treatment.

ASCO: Crizotinib tolerated, active in pediatric patients

ASCO: Crizotinib tolerated, active in pediatric patients

Crizotinib active in anaplastic large cell lymphoma; neuroblastoma; other tumors with ALK mutations.

<i>ATRX</i> Mutation Linked With Age at Diagnosis of Neuroblastoma

ATRX Mutation Linked With Age at Diagnosis of Neuroblastoma

Stratification by age at diagnosis shows more mutations found in children diagnosed at an older age.

Childhood cancer survivors more likely to have future GI problems

People who underwent cancer therapy as children have a heightened risk of developing gastrointestinal (GI) complications later in life, a new study shows.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs